Literature DB >> 15684480

Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by tryptanthrin.

Takahiro Motoki1, Yoichiro Takami, Yasuyuki Yagi, Akihiro Tai, Itaru Yamamoto, Eiichi Gohda.   

Abstract

In addition to regulation of normal cell functions, hepatocyte growth factor (HGF) has also been shown to be involved in malignant cell transformation and in growth, invasion and metastasis in cancer cells. Inhibitors of HGF production have a potential for interfering with malignant cell transformation and progression of tumors. We found that tryptanthrin, one of the major compounds extracted from the medicinal plant Polygonum tinctorium, which is known for its antitumor activity, strongly inhibited HGF production stimulated by various HGF inducers in human dermal fibroblasts. HGF production induced by phorbol 12-myristate 13-acetate (PMA) was potently inhibited by tryptanthrin without any appreciable cytotoxic effect. Tryptanthrin also inhibited HGF production induced by epidermal growth factor (EGF) and platelet-derived growth factor. Moreover, proliferation of the fibroblasts induced by the two growth factors was potently suppressed by tryptanthrin to the level of proliferation of unstimulated fibroblasts. However, tryptanthrin did not inhibit HGF production induced by the protein kinase A-activating agents cholera toxin and 8-bromo-cAMP. These effects of tryptanthrin were different from the effects of transforming growth factor beta1 and dexamethasone, both of which inhibit HGF production induced by all the above inducers. Upregulations of HGF gene expression by PMA and EGF were also inhibited by tryptanthrin. Activation of the mitogen-activated protein kinase (MAPK) signaling pathway is crucial for PMA-induced HGF production, but tryptanthrin did not attenuate phosphorylation of MAPK induced by PMA. These results indicate that tryptanthrin potently inhibited induction of HGF production probably through events downstream of MAPK activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684480     DOI: 10.1248/bpb.28.260

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  Kourokhitin, a potential drug containing two active substances.

Authors:  A M Popov; Yu M Gafurov; T V Moskovkina; A V Kachanov; O N Krivoshapko; S E Petrovicheva; V A Stonik
Journal:  Dokl Biochem Biophys       Date:  2009 May-Jun       Impact factor: 0.788

Review 2.  Biologically active quinoline and quinazoline alkaloids part II.

Authors:  Xiao-Fei Shang; Susan L Morris-Natschke; Guan-Zhou Yang; Ying-Qian Liu; Xiao Guo; Xiao-Shan Xu; Masuo Goto; Jun-Cai Li; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2018-02-27       Impact factor: 12.944

3.  7,9-Dichloro-6H,12H-indolo[2,1-b]quinazoline-6,12-dione.

Authors:  Peter Grundt; Kelsi A Douglas; Bogdana Krivogorsky; Victor N Nemykin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-05-29

4.  DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria.

Authors:  Jayesh Antony; Minakshi Saikia; V Vinod; Lekshmi R Nath; Mohana Rao Katiki; M S R Murty; Anju Paul; A Shabna; Harsha Chandran; Sophia Margaret Joseph; Kumar S Nishanth; Elizabeth Jayex Panakkal; I V Sriramya; I V Sridivya; Sophia Ran; S Sankar; Easwary Rajan; Ruby John Anto
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.